Promising Pre-clinical Data Supporting BerGenBio's Pipeline to be Published and Presented at Upcoming Leading Conferences
• Bemcentinib active in pre-clinical models of IPF and NASH• IPF and cirrhotic NASH patients with aggressive disease identified by AXL blood based biomarker• BGB601 (partnered AXL ADC drug candidate) ...
Page (1) of 1 - 04/13/18||
(April 13, 2018)
This article is no longer available,but here are some related topics.
USA, Inc.,Medicine,Disease,Cancer,Surgery,Medication,Womens Health,Science,Lifestyle,Medical,Biology,Cancer,Other,
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved